F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

The FDA has granted expedited approval to daraxonrasib, a groundbreaking first-of-a-kind pill for the most common form of pancreatic cancer. This drug targets a mutated protein fueling tumor growth in over 90% of cases, an approach that previously eluded researchers. In a key clinical trial, patients treated with daraxonrasib lived twice as long as those receiving chemotherapy. This landmark approval offers U.S. patients a more effective treatment against one of the deadliest types of cancer.